<DOC>
	<DOCNO>NCT00396409</DOCNO>
	<brief_summary>Efficacy/ safety combination anti-IgE ( Omalizumab ) specific immunotherapy ( Depigoid ) patient adequately control seasonal allergic asthma comorbid seasonal allergic rhinoconjunctivitis .</brief_summary>
	<brief_title>Efficacy/ Safety Omalizumab Patients With Seasonal Allergic Asthma Seasonal Allergic Rhinoconjunctivitis</brief_title>
	<detailed_description>This open-label extension period previously randomize , multicenter , double-blind , placebo-controlled , parallel-group trial demonstrate benefit pre- co-seasonal combination therapy anti-IgE ( omalizumab ) specific immunotherapy ( Depigoid ) patient seasonal allergic asthma co-morbid seasonal allergic rhinoconjunctivitis . During open-label period , patient receive Depigoid monotherapy two follow-up season every 4 week , 26 injection total . The extension period perform evaluate influence omalizumab follow-up treatment Depigoid seasonal asthma . This study follow-up core IGE025ADE03 study , patient receive omalizumab treatment . In follow-up study , patient receive omalizumab .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Males female race 1245 year age body weight ≥ 20 kg ≤ 150 kg total serum IgE level ≥ 30 ≤ 700 IU/ml ( suitable weight dose ) Patients diagnosis adequately control seasonal grass pollen ( and/or rye pollen ) allergic asthma concomitant seasonal allergic rhinoconjunctivitis within &gt; 2 previous season patient positive RAST ( &gt; CAP2 ) result grass pollen ( and/or rye pollen ) specific IgE screening ( Visit 1 ( V1 ) within previous 12 month . Patients FEV1 &gt; 80 % predict normal value patient screen [ V1 ] ( demostrable least 6 hour last short act B2 agonist use 12 hour last long B2 act agonist use ) . Females childbearing potential : pregnancy , birth control , breastfeed Concurrent diseases/conditions history diseases/conditions 1. patient positive history significant clinical manifestation allergy result sensitization tree pollen allergen , weed allergen perennial allergen ( e.g . Aspergillus spore , animal dander , house dust mite ) . 2. patient history food drug relate severe anaphylactoid anaphylactic reaction ( ) . Ingredient hypersensitivity 1. patient know hypersensitivity ingredient , include excipients ( sucrose , histidine , polysorbate 20 ) study medication , immunotherapy , drug relate Omalizumab ( e.g. , monoclonal antibody , polyclonal gamma globulin ) . 2. patient hypersensitivity trail 's asthma rescue escalationmedication relate drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>